Class 4 medicines defect information: Inhixa solution for injection in pre-filled syringe (EL (18)A/07)

By 19th April 2018 News, UK Pharma No Comments

Product information
MDR number

MDR 049-12/17

Company name

Techdow Europe AB

Product description

Inhixa solution for injection in pre-filled syringe 2,000 IU (20 mg) in 0.2 mL; 4,000 IU (40 mg) in 0.4 mL; 6,000 IU (60 mg) in 0.6 mL; 8,000 IU (80 mg) in 0.8 mL; 10,000 IU (100 mg) in 1.0 mL.

Marketing Authorisation number

EU/1/16/1132/012
EU/1/16/1132/014
EU/1/16/1132/016
EU/1/16/1132/018
EU/1/16/1132/020

Brief description of the problem

Techdow Europe AB has issued the Direct Healthcare Professional Communication (DHCP) attached due to rare cases of premature self-activation of the safety device in unused, unopened pre-filled Inhixa syringes as shown in the DHCP diagrams. When premature activation has occurred, administration is not possible.
Advice for healthcare professionals

To minimise the risk of missed doses:

Pharmacists should visually check all Inhixa syringes before dispensing to check if they are affected by the self-activation defect as shown in the DHCP diagrams. Do not open the syringe blisters.
Individual syringes that are affected by the self-activation defect should not be dispensed to patients.
Pharmacists should make sure they have sufficient stock of Inhixa available as replacements.